DMAA (1,3-Dimethylamylamine): Evidence, Label Amounts and Legal Status

DMAA at a glance

DMAA (1,3-dimethylamylamine), also sold as methylhexanamine or “geranium extract”, is a stimulant first patented in 1944 as a nasal decongestant. It narrows blood vessels and raises blood pressure, and case reports link products containing it to strokes, heart attacks and deaths during exertion. Most laboratories that tested geranium plants and oils found no DMAA in them. WADA names it in class S6, the MHRA treats products with DMAA as unlicensed medicines, and the FDA calls DMAA supplements illegal.

Evidence: Human trials (small studies, mostly of blood pressure and blood markers) · Updated 20 November 2026

What DMAA is

DMAA stands for 1,3-dimethylamylamine. The WADA List gives its chemical name, 4-methylhexan-2-amine, with methylhexaneamine as another name. The FDA notes that labels may also call it 1,3-dimethylpentylamine, 2-amino-4-methylhexane or geranamine. It adds that “geranium extract” or Pelargonium graveolens extract on a label may indicate DMAA. Both Hammer Labz products that contain it simply say “DMAA”.

DMAA was patented in 1944 as a nasal decongestant. According to the FDA, it was once approved as a drug for that use, is no longer approved and has no recognised medical use today. Decades later it reappeared in products sold for sports performance and weight loss, and as a recreational stimulant.

The geranium dispute. Supplement makers argued that DMAA is a natural part of geranium (Pelargonium graveolens), which would make it a dietary ingredient. Its presence in geranium was first reported in 1996, in a paper whose identification was later questioned. Two later studies reported finding it in plants and oil sourced from China, while most other analyses found none.

In a multi-centre study published in 2015, four laboratories each tested the same 18 plant samples from six Pelargonium species and 9 oils from around the world. None of them detected DMAA. A 2012 study compared DMAA from 13 supplements with synthetic DMAA. The ratio of its stereoisomers, forms with the same atoms arranged differently in space, was indistinguishable. The FDA says it knows of no reliable science showing that DMAA exists naturally in plants.

How DMAA works

DMAA is a sympathomimetic and a potent pressor agent: it acts on the system that adrenaline and noradrenaline control and pushes blood pressure up. The FDA explains that it narrows blood vessels and arteries. In anaesthetised rats, DMAA worked mainly indirectly, by releasing noradrenaline. It raised heart rate and blood pressure across the same range of doses.

DMAA also acts on the brain’s dopamine system. In cells carrying the human dopamine transporter, it blocked dopamine uptake and behaved like amphetamine-type substances at that transporter. In mice and rats, it produced cocaine-like effects in drug discrimination tests and a conditioned place preference. The authors read these results as a potential for abuse.

Evidence

Human trials. The controlled studies in people are small and mostly measure blood pressure, heart rate and blood markers. In a double-blind crossover study, 10 young healthy men and women took DMAA, caffeine or both on separate days. DMAA raised systolic and diastolic blood pressure without raising heart rate. The rise was generally bigger with the higher of two amounts, and it peaked when that amount was combined with caffeine. Fifty young healthy men took placebo, caffeine, DMAA or both for 12 weeks. The authors found no significant change in any measured outcome, apart from small shifts over time in urine pH and blood CO2. The measures included blood pressure, an ECG and blood tests.

A 2017 critical review found 16 studies of DMAA’s effects: eight case reports and eight experimental studies. It describes the experimental studies as low powered, several of them from a single research group with industry ties. Results were mixed, with blood pressure rising after single doses. The review calls the evidence on adverse effects shallow, including the amount at which they may begin.

Case reports. Published reports describe serious events in people who took products containing DMAA. Two US soldiers collapsed from cardiac arrest during physical exertion and died. Three adults had bleeding in the brain after recreational use. A 26-year-old man had a stroke with bleeding in the brain shortly after taking the pre-workout Jack3d, which listed geranamine. A previously healthy 22-year-old man had a heart attack after three weeks of daily pre-workout supplements with DMAA and Citrus aurantium. A 21-year-old man went into cardiac arrest after a workout supplement with DMAA. Several of these products combined DMAA with caffeine or other stimulants. The soldier report frames its concern around DMAA in combination with other ingredients, and the heart attack report notes that no safety data exist on such combinations. Of 56 exposures to DMAA products reported to Texas poison centres in 2010–2011, 80.4% had outcomes classed as not serious. More than half of those exposed were children aged five or under. The study’s author notes that some effects may come from other ingredients, such as caffeine.

The FDA advises consumers not to buy or use products sold as dietary supplements that contain DMAA. If you have high blood pressure or a heart condition, or take any medication, ask a doctor about any stimulant product before you use it.

Amounts on labels

Two Hammer Labz labels list DMAA:

  • Atomic Strength: 75 mg DMAA per scoop (10 g).
  • Oxy-Dren: 70 mg DMAA. The panel gives the serving size as “60 capsules”, so it does not show how many capsules the 70 mg refers to.

Both labels combine DMAA with other stimulants. Atomic Strength also lists 100 mg DMHA and 250 mg dicaffeine malate. Oxy-Dren lists 200 mg caffeine, 50 mg Ephedra vulgaris, 30 mg synephrine HCl and two forms of yohimbine, 2 mg each.

These are label amounts only. For stimulants without authorisation for use in people, we publish no amounts from studies and no “typical” amounts; see how we review.

Legal and anti-doping status

Status checked on 20 November 2026.

  • WADA: the 2026 and 2027 Lists name 4-methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexaneamine) in class S6, stimulants, prohibited in competition.
  • UK: in a 2017 statement, the MHRA said that DMAA is found in unlicensed medicines marketed as sports supplements. It said that when it finds such products, it takes urgent action to remove them from sale, as it first did in 2012.
  • EU, medicines: we found no entry for DMAA, methylhexanamine, 1,3-dimethylamylamine or 4-methylhexan-2-amine in the European Medicines Agency’s database of medicines authorised in the EU and EEA.
  • EU, food: the EU novel food catalogue has no entry under these names, and a missing entry does not settle an ingredient’s status. In its guidance for food inspectors, Sweden’s food agency gives DMAA as an example of a substance that can make a food a health risk under EU food law. It adds that DMAA found in performance supplements has appeared in several EU rapid alerts (RASFF).
  • US: the FDA says DMAA is not a dietary ingredient and that DMAA products sold as supplements are illegal. It considers DMAA added to them an unsafe food additive. In 2019 a US federal appeals court ruled that DMAA is not a dietary ingredient.

Not for drug-tested athletes: Atomic Strength and Oxy-Dren list DMAA. Atomic Strength also lists DMHA, octopamine and methyl synephrine, and Oxy-Dren lists ephedra; WADA names octodrine, octopamine, oxilofrine (methylsynephrine) and ephedrine in class S6 as well. Status differs by country and changes over time.

Found in

Hammer Labz (brand page)

  • Atomic Strength
  • Oxy-Dren

Sources

  1. Product labels: Hammer Labz supplement facts panels for Atomic Strength and Oxy-Dren, as listed in November 2026.
  2. Gee P, Tallon C, Long N, et al. (2012). Use of recreational drug 1,3 Dimethylamylamine (DMAA) associated with cerebral hemorrhage. Ann Emerg Med, 60(4), 431–434. PMID: 22575212.
  3. U.S. Food and Drug Administration. DMAA in Products Marketed as Dietary Supplements. Content current as of 22 February 2023. Accessed 20 November 2026.
  4. Elsohly MA, Gul W, Elsohly KM, et al. (2012). Pelargonium oil and methyl hexaneamine (MHA): analytical approaches supporting the absence of MHA in authenticated Pelargonium graveolens plant material and oil. J Anal Toxicol, 36(7), 457–471. PMID: 22733691.
  5. Gauthier TD (2013). Evidence for the Presence of 1,3-Dimethylamylamine (1,3-DMAA) in Geranium Plant Materials. Anal Chem Insights, 8, 29–40. PMID: 23843687.
  6. ElSohly MA, Gul W, Tolbert C, et al. (2015). Methylhexanamine is not detectable in Pelargonium or Geranium species and their essential oils: A multi-centre investigation. Drug Test Anal, 7(7), 645–654. PMID: 25346500.
  7. Zhang Y, Woods RM, Breitbach ZS, et al. (2012). 1,3-Dimethylamylamine (DMAA) in supplements and geranium products: natural or synthetic? Drug Test Anal, 4(12), 986–990. PMID: 22786761.
  8. Alsufyani HA, Docherty JR (2019). Methylhexaneamine causes tachycardia and pressor responses indirectly by releasing noradrenaline in the rat. Eur J Pharmacol, 843, 121–125. PMID: 30395850.
  9. Small C, Cheng MH, Belay SS, et al. (2023). The Alkylamine Stimulant 1,3-Dimethylamylamine Exhibits Substrate-Like Regulation of Dopamine Transporter Function and Localization. J Pharmacol Exp Ther, 386(2), 266–273. PMID: 37348963.
  10. Dolan SB, Gatch MB (2015). Abuse liability of the dietary supplement dimethylamylamine. Drug Alcohol Depend, 146, 97–102. PMID: 25481853.
  11. Bloomer RJ, Harvey IC, Farney TM, et al. (2011). Effects of 1,3-dimethylamylamine and caffeine alone or in combination on heart rate and blood pressure in healthy men and women. Phys Sportsmed, 39(3), 111–120. PMID: 22030947.
  12. Bloomer RJ, Farney TM, Harvey IC, et al. (2013). Safety profile of caffeine and 1,3-dimethylamylamine supplementation in healthy men. Hum Exp Toxicol, 32(11), 1126–1136. PMID: 23424215.
  13. Dunn M (2017). Have prohibition policies made the wrong decision? A critical review of studies investigating the effects of DMAA. Int J Drug Policy, 40, 26–34. PMID: 27856133.
  14. Eliason MJ, Eichner A, Cancio A, et al. (2012). Case reports: Death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA). Mil Med, 177(12), 1455–1459. PMID: 23397688.
  15. Young C, Oladipo O, Frasier S, et al. (2012). Hemorrhagic stroke in young healthy male following use of sports supplement Jack3d. Mil Med, 177(12), 1450–1454. PMID: 23397687.
  16. Smith TB, Staub BA, Natarajan GM, et al. (2014). Acute myocardial infarction associated with dietary supplements containing 1,3-dimethylamylamine and Citrus aurantium. Tex Heart Inst J, 41(1), 70–72. PMID: 24512406.
  17. Karnatovskaia LV, Leoni JC, Freeman ML (2015). Cardiac arrest in a 21-year-old man after ingestion of 1,3-DMAA-containing workout supplement. Clin J Sport Med, 25(1), e23–e25. PMID: 24878759.
  18. Forrester M (2013). Exposures to 1,3-dimethylamylamine-containing products reported to Texas poison centers. Hum Exp Toxicol, 32(1), 18–23. PMID: 23060409.
  19. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 20 November 2026.
  20. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 20 November 2026.
  21. Medicines and Healthcare products Regulatory Agency (2017). MHRA warns athletes to avoid potentially dangerous DMAA. Press release, 30 January 2017. Accessed 20 November 2026.
  22. European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 20 November 2026.
  23. European Commission. EU Novel Food status catalogue. Catalogue data retrieved 19 November 2026.
  24. Livsmedelsverket (Swedish Food Agency). Risker med kosttillskott [Risks of food supplements]. Kontrollwiki, guidance for food control authorities, updated 20 August 2026. In Swedish. Accessed 20 November 2026.